Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy

In patients with hypogammaglobulinemia secondary to chronic lymphocytic leukemia (CLL) or multiple myeloma (MM), intravenous immune globulin (IVIg) may be administered to reduce the risk of infection. Since 2013, IVIg products have carried a boxed safety warning about the risk of thromboembolic even...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Ammann, Eric M., Jones, Michael P., Link, Brian K., Carnahan, Ryan M., Winiecki, Scott K., Torner, James C., McDowell, Bradley D., Fireman, Bruce H., Chrischilles, Elizabeth A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2016
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4713161/
https://ncbi.nlm.nih.gov/pubmed/26443622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-647552
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky